• The acridine orange derivative amsacrine (National Services Center No. 249992) was used to treat a patient with T-cell acute lymphoblastic leukemia (ALL). A 17-year-old boy had a tumor lysis syndrome after a single 200 mg/sq m dose of amsacrine. This was followed by a prolonged period of marrow hypoplasia leading to death from infection. Review of the literature and our own experience would suggest that T-cell ALL may be exquisitely sensitive to amsacrine.
(Arch Intern Med 1983;143:165-166)
Vogler WR, Morris JG, Winton EF. Acute Tumor Lysis in T-Cell Leukemia Induced by Amsacrine. Arch Intern Med. 1983;143(1):165–166. doi:10.1001/archinte.1983.00350010177034
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: